TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Commentary|Videos|August 12, 2024
Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis
Author(s)Danielle E. Hammond, MD, FRCP(C)
Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.
Advertisement
Advertisement
Related to this article
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
5